Taillé C, Chanez P, Devouassoux G, et al. - Given the availability of mepolizumab in France as part of an early access programme for patients experiencing severe eosinophilic asthma (nominative Temporary Use Authorisation [nATU]) prior to its commercialisation, researchers undertook this retrospective, observational analysis to characterize patients who took mepolizumab in the nATU. Data were collected from the hospital medical records of patients up to 24 months following treatment start. On average 5.8 exacerbations/patient/year were encountered by patients at baseline, 0.6 and 0.5 of which needed hospitalisation and emergency department visits, respectively. A follow-up of 24 months revealed improvement in these values to 0.6, 0.1 and 0.1 exacerbations/patient/year, respectively, as well as improvement in mean blood eosinophil counts from 722 cells·µL⁻¹ at baseline to 92 cells·µL⁻¹. The results from clinical trials were corroborated in this work, showing the link of mepolizumab with significant improvements in many clinically meaningful outcomes as well as its favourable safety profile in a sample of patients with severe eosinophilic asthma, outside of the controlled environment of a clinical trial.